CELLECTAR BIOSCIENCES, INC.

FLORHAM PARK, NJ How do I update this listing?

Cellectar Biosciences is based out of Florham Park. Novelos Therapeutics Inc. a biopharmaceutical company commercializes oxidized glutathione-based compounds for the treatment of cancer and hepatitis in the United States.Whalewisdom has at least 80 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2021-01-08. The notice included securities offered of Equity

Create Alert

Contact Info

cellectar biosciences, inc.
100 CAMPUS DRIVE
FLORHAM PARK NJ    07932

Business Phone: (608) 441-8120
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2021-01-08 D PHARMACEUTICALS Equity 20,499,993 20,499,993 0
2019-05-31 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 14,645,000 5,045,000 9,600,000
2017-10-13 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 7,766,164 7,766,164 0
2014-08-15 D PHARMACEUTICALS Debt 1,000,000 617,500 382,500
2011-04-14 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 5,134,903 5,134,903 0
2009-11-19 D/A PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 9,000,000 9,000,000 0
2009-09-09 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 9,000,000 3,500,000 5,500,000
2009-02-26 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 32,250,000 32,250,000 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
CHAD J. KOLEAN subscription required
    EXECUTIVE OFFICER
CHARLES T. BERNHARDT subscription required
    EXECUTIVE OFFICER
CHRISTOPHER J. PAZOLES subscription required
    EXECUTIVE OFFICER
DAVID B. MCWILLIAMS subscription required
    DIRECTOR
DOUGLAS J. SWIRSKY subscription required
    DIRECTOR
DOV ELEFANT subscription required
    EXECUTIVE OFFICER
ELIAS NYBERG subscription required
    EXECUTIVE OFFICER
FREDERICK W. DRISCOLL subscription required
    DIRECTOR
HARRY S. PALMIN subscription required
    DIRECTOR EXECUTIVE OFFICER
HOWARD M. SCHNEIDER subscription required
    DIRECTOR
JAMES V. CARUSO subscription required
    EXECUTIVE OFFICER DIRECTOR
JAMES S. MANUSO subscription required
    DIRECTOR
JAMEY P. WEICHERT subscription required
    DIRECTOR EXECUTIVE OFFICER
JARROD LONGCOR subscription required
    EXECUTIVE OFFICER
JOANNE M. PROTANO subscription required
    EXECUTIVE OFFICER
JOHN FRIEND subscription required
    DIRECTOR
JOHN E. FRIEND II subscription required
    EXECUTIVE OFFICER
JOHN P. HAMILL subscription required
    EXECUTIVE OFFICER
JOHN E. NEIDERHUBER subscription required
    DIRECTOR
JOHN NEIS subscription required
    DIRECTOR
KIM HAWKINS subscription required
    EXECUTIVE OFFICER
KRISTIN C. SCHUHWERK subscription required
    EXECUTIVE OFFICER
MICHAEL J. DOYLE subscription required
    DIRECTOR
MICHAEL F. TWEEDLE subscription required
    DIRECTOR
PAUL BERNS subscription required
    DIRECTOR
SIMM FASS subscription required
    DIRECTOR
SIMON PEDDER subscription required
    EXECUTIVE OFFICER DIRECTOR
STEFAN LOREN subscription required
    DIRECTOR
STEPHEN A. HILL subscription required
    DIRECTOR
THOMAS ROCKWELL MACKIE subscription required
    DIRECTOR

Elevate your investments